Drug intelligence / Profile preview

chebulinic acid

Development stage
Preclinical
Lead developer
CSIR-Central Drug Research Institute
Modality
Small Molecules
01

Overview

Chebulinic acid is a naturally occurring hydrolyzable tannin polyphenol isolated from medicinal plants such as *Terminalia chebula* and studied as an experimental small-molecule anticancer and antioxidant agent. Preclinical work, including the provided breast cancer study, suggests it can inhibit tumor cell proliferation and induce apoptosis, but its mechanism is not established as a single validated drug-target interaction; instead, reported activity is pleiotropic and likely related to polyphenolic modulation of oxidative stress, cell-cycle regulation, and apoptosis-associated signaling. It is not an approved pharmaceutical product, and current evidence supports it as a research-stage natural product rather than a clinically developed drug, with formulation work exploring nanoparticle delivery to improve exposure and antitumor activity in models of breast cancer.

Other names
chebulinic acid
02

Targets

ORM1 (Alpha-1-acid glycoprotein 1)CD4 (T lymphocyte surface antigen)CagA (Cytotoxin-associated gene A protein)HSA Site II (Human serum albumin Site II)DNA gyrase

Beyond the preview

Go deeper on chebulinic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chebulinic acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call